Philippe Merle
菲利普·梅尔勒
MD, PhD
Professor of Hepatology, Head of Liver Tumor Unit肝病学教授，肝脏肿瘤科主任
👥Biography 个人简介
Philippe Merle is a leading hepato-oncologist at Lyon University Hospital with pivotal contributions to HCC immunotherapy trials, including the CheckMate 040 nivolumab study. His research spans HCC biomarker discovery and translation of immunotherapy into French and European clinical practice.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CheckMate 040 – Nivolumab in HCC
Key investigator in the CheckMate 040 phase I/II trial demonstrating durable responses with nivolumab in sorafenib-experienced HCC patients, supporting accelerated FDA approval.
HCC Biomarker Research
Led translational studies identifying predictive biomarkers for immunotherapy response in HCC, contributing to patient stratification strategies for checkpoint inhibitor trials.
Representative Works 代表性著作
Nivolumab in Sorafenib-Naive and -Experienced Patients with Advanced Hepatocellular Carcinoma (CheckMate 040)
Journal of Clinical Oncology (2018)
Phase I/II data showing durable objective responses with nivolumab across HCC patient cohorts.
Predictive Biomarkers for Immunotherapy in Hepatocellular Carcinoma
Hepatology (2022)
Review of tumor microenvironment and molecular biomarkers predictive of checkpoint inhibitor benefit in HCC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 菲利普·梅尔勒 的研究动态
Follow Philippe Merle's research updates
留下邮箱，当我们发布与 Philippe Merle（Hospices Civils de Lyon, Lyon University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment